PHAR

Business Context and Reporting Period

Pharming Group N.V. (Pharming) filed a Form 6-K on March 12, 2026, reporting preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025. The company is a global biopharmaceutical firm focused on rare diseases, with its primary commercial products being RUCONEST® (for hereditary angioedema) and Joenja® (leniolisib, for APDS).

Key Financial Metrics

Product Revenue Breakdown (Full Year 2025):

• RUCONEST®: $317.9 million (26% increase YoY).
• Joenja®: $58.2 million (29% increase YoY).

Material Changes vs. Prior Period

• Profitability Inflection: The company achieved a full-year operating profit of $25.8 million in 2025, reversing an $8.6 million operating loss in 2024. Net income turned positive ($2.5 million) from a net loss of $11.8 million.
• Revenue Growth: Total revenue grew 27% year-over-year, driven by volume increases in both RUCONEST® (20% unit sales growth in the U.S.) and Joenja® (37% volume growth).
• Cost Structure: Cost of sales increased 29% due to higher unit volumes, royalty payments to Novartis, and a $5.0 million sales milestone payment for Joenja®. Operating expenses included $29.7 million in one-time Abliva acquisition-related costs.
• Balance Sheet: Intangible assets increased by $74.5 million primarily due to the acquisition of Abliva AB. Cash and cash equivalents increased significantly to $145.3 million, with total liquid assets (including marketable securities) at $181.1 million.

Guidance, Outlook, and Risks

2026 Guidance

• Revenue: Expected to range between $405.0 million and $425.0 million (8% to 13% growth).
• Operating Expenses: Anticipated between $330 million and $335 million, including $60 million in incremental R&D for pipeline advancement and $9 million in structural G&A cost reductions.

Management Commentary & Pipeline

• Joenja® Expansion: Management highlighted accelerating growth with 120 patients on paid therapy in the U.S. (up 25% from 2024). A Complete Response Letter (CRL) was received from the FDA regarding the pediatric label expansion (ages 4-11); a Type A meeting is scheduled for March 2026 to discuss resubmission.
• Regulatory Milestones: EMA approval for Joenja® in the EEA is expected in H1 2026. A PMDA decision in Japan is expected by end of March 2026.
• Pipeline Catalysts: Phase II readouts for leniolisib in broader primary immunodeficiencies are expected in H2 2026. Enrollment for the pivotal FALCON study of napazimone (KL1333) is on track to complete in 2026, with data readout anticipated in late 2027.

Risks and Contingencies

• Regulatory Uncertainty: The FDA CRL for the pediatric label expansion requires additional data and clarification, creating timing uncertainty for that specific indication.
• Foreign Exchange: The strengthening of the euro against the U.S. dollar resulted in a $7.2 million foreign currency loss in 2025, impacting the finance result.
• Acquisition Integration: Significant one-time costs related to the Abliva acquisition impacted operating margins in 2025.

Investor Verification Checklist

• Regulatory Path for Pediatric Joenja®: Verify the outcome of the March 2026 FDA Type A meeting and the timeline for resubmission of the sNDA for ages 4-11.
• 2026 Expense Execution: Monitor whether the company achieves the projected $9 million in structural G&A cost reductions to offset the $60 million increase in R&D spend.
• Pipeline Milestones: Track the completion of enrollment for the FALCON study (napazimone) and the H2 2026 readouts for leniolisib in non-APDS PIDs.
• Cash Burn vs. Generation: Confirm that positive operating cash flow continues to fund the $60 million incremental R&D spend without requiring immediate external financing.
• FX Sensitivity: Assess the impact of EUR/USD fluctuations on future reported earnings, given the company's significant U.S. revenue base and European headquarters.